Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

imatinib (Rx)Brand and Other Names:Gleevec

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

tablet

  • 100mg
  • 400mg
more...

Acute Lymphoblastic Leukemia

Indicated for adults with relapsed or refractory Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL)

600 mg PO qDay

Myelodysplastic/Myeloproliferative Diseases

Indicated in adults with myelodysplastic/ myeloproliferative diseases associated with platelet-derived growth factor receptor gene re-arrangements

400 mg PO qDay

Hypereosinophilic Syndrome/Eosinophilic Leukemia

Indicated for adults with hypereosinophilic syndrome and/or chronic eosinophilic leukemia who have the FIP1L1-PDGFR-alpha fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFR-alpha fusion kinase negative or unknown

400 mg PO qDay

In patients with demonstrated F1P1L1-PDGFR-alpha fusion kinase: 100 mg PO qDay; may increase to 400 mg qDay in the absence of adverse drug reactions if assessments demonstrate an insufficient response to therapy

Chronic Myeloid Leukemia

Chronic phase

  • Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase
  • 400 mg PO qDay
  • Chronic phase after failure of interferon-alpha therapy: May increase to 600 mg/day in the absence of severe adverse drug reaction and severe nonleukemia related neutropenia or thrombocytopenia in the following circumstances: disease progression (at any time), failure to achieve a satisfactory hematologic response after at least 3 months of treatment, failure to achieve a cytogenetic response after 6-12 months of treatment, or loss of a previously achieved hematologic or cytogenetic response

Accelerated phase or blast crisis

  • 600 mg PO qDay
  • May increase to 400 mg PO q12hr in the absence of severe adverse drug reaction and severe nonleukemia related neutropenia or thrombocytopenia in the following circumstances: disease progression (at any time), failure to achieve a satisfactory hematologic response after at least 3 months of treatment, failure to achieve a cytogenetic response after 6-12 months of treatment, or loss of a previously achieved hematologic or cytogenetic response

Dermatofibrosarcoma Protuberans

Indicated for adults with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans

400 mg PO q12hr

Mastocytosis

Indicated for adults with aggressive systemic mastocytosis without the D816V c-Kit mutation or with c-Kit mutational status unknown

Without D816V c-Kit mutation: 100 mg PO qDay

c-Kit mutational status unknown: 400 mg PO qDay if not responding to other therapies

ASM associated with eosinophilia (a clonal hematological disease related to the fusion kinase FIP1L1-PDGFR-alpha): 100 mg PO qDay initially, may increase to 400 mg/day in absence of adverse effects if response to therapy is insufficient

Gastrointestinal Stromal Tumors

Unresectable and/or metastatic malignant GIST

  • 400 mg PO qDay; may increase to 400 mg BID in patients showing clear signs or symptoms of disease progression at a lower dose and in the absence of severe adverse drug reactions

Adjuvant treatment following complete gross resection of GIST

  • 400 mg PO qDay x3 years

Dosage Modifications

Withhold treatment if fluid retention

Hematologic toxicity

  • Generally, discontinue if ANC <1000/mm³ and/or Plts <50,000/mm³
  • Resume when ANC >1500/mm³ and Plts >75,000/mm³
  • See Mfr's PI for specifics

Hepatotoxicity

  • Withhold if bilirubin >3x ULN or ALT/AST >5x ULN
  • Resume after bilirubin <1.5x ULN and ALT/AST <2.5x ULN at a reduced dose (ie, 400 mg to 300 mg; 600 mg to 400 mg; 800 mg to 600 mg)
  • Withhold if severe hepatotoxicity; once resolved, reduce dose by 25%

Pulmonary Arterial Hypertension (Orphan)

Orphan indication sponsor

  • Novartis Drug Regulatory Affairs; East Hanover, NJ 07936-1080

Progressive Multifocal Leukencephalopathy (Orphan)

Orphan designation for treatment of PML

Sponsor

  • Inhibikase Therapeutics, Inc; 3350 Riverwood Parkway, Suite 1927; Atlanta, GA 30339

Dosing Considerations

Monitor

  • CBC qWeek x 4, then q2Weeks x 2, then periodically
  • LFTs at baseline and qMonth
  • Signs of fluid retention

Administration

Take with meal and a large glass of water

For patients unable to swallow, tablets may be dispersed in water or apple juice

Treatment may be continued as long as there is no evidence of progressive disease or unacceptable toxicity

Dosage Forms & Strengths

tablet

  • 100mg
  • 400mg
more...

Chronic Myeloid Leukemia

Indicated for newly diagnosed adult and pediatric patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase

<1 year: Safety and efficacy not established

≥1 year: 340 mg/m²/day PO; not to exceed 600 mg/day 

Acute Lymphoblastic Leukemia

Indicated for treatment of newly diagnosed children with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL)

<1 year: Safety and efficacy not established

≥1 year: 340 mg/m²/day PO; not to exceed 600 mg/day 

Dosage Modifications

Withhold treatment if fluid retention

Hematologic toxicity

  • Generally, discontinue if ANC <1000/mm³ and/or Plts <50,000/mm³
  • Resume when ANC >1500/mm³ and Plts >75,000/mm³
  • See Mfr's PI for specifics

Hepatotoxicity

  • Withhold if bilirubin >3x ULN or ALT/AST >5x ULN
  • Resume after bilirubin <1.5x ULN and ALT/AST <2.5x ULN at a reduced dose (ie, from 340 mg/m²/day to 260 mg/m²/day)
  • Withhold if severe hepatotoxicity; once resolved reduce dose by 25%

Dosing Considerations

Monitor

  • CBC qWeek x 4, then q2Weeks x 2, then periodically
  • LFTs at baseline and qMonth
  • Signs of fluid retention

Administration

Take with meal and large glass of water

For patients unable to swallow, tablets may be dispersed in water or apple juice

Treatment may be continued as long as there is no evidence of progressive disease or unacceptable toxicity

Next

Interactions

Interaction Checker

imatinib and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            >10%

            Edema (53%)

            Neutropenia (Grade 3: 7-27%; Grade 4: 3-48%)

            Nausea (43%)

            Muscle cramps (35%)

            Musculoskeletal pain (34%)

            Thrombocytopenia (Grade 3: 1-31%; Grade 4: 1-34%)

            Rash (32%)

            Fatigue (31%)

            Diarrhea (30%)

            Headache (29%)

            Arthralgia (27%)

            Abd pain (23%)

            Myalgia (21%)

            Nasopharyngitis (19%)

            Hemorrhage (19%)

            Vomiting (15%)

            Dyspepsia (15%)

            Cough (13%)

            Dizziness (13%)

            URT infection (13%)

            Fever (12%)

            Weight gain (12%)

            Hepatotoxicity (6-12%)

            Insomnia (11%)

            1-10%

            Flushing

            Palpitation

            Dry skin

            Erythema

            Metabolic hyperglycemia

            Stomatitis/mucositis

            Lymphopenia

            <1%

            Aplastic anemia

            Atrial fibrillation

            Avascular necrosis

            Cardiac failure

            Cardiogenic shock

            Embolism

            Eosinophilia

            Postmarketing Reports

            Nervous system disorders: Cerebral edema

            Eye disorders: Vitreous hemorrhage

            Cardiac disorders: Pericarditis, cardiac tamponade

            Vascular disorders: Thrombosis/embolism, anaphylactic shock

            Respiratory, thoracic and mediastinal disorders: Acute respiratory failure, interstitial lung disease

            Gastrointestinal disorders: Ileus/intestinal obstruction, tumor hemorrhage/tumor necrosis, gastrointestinal perforation, diverticulitis; gastric antral vascular ectasia

            Skin and subcutaneous tissue disorders: Ichenoid keratosis, lichen planus, toxic epidermal necrolysis, palmar-plantar erythrodysesthesia syndrome, drug rash with eosinophilia and systemic symptoms (DRESS)

            Musculoskeletal and connective tissue disorders: Avascular necrosis/hip osteonecrosis, rhabdomyolysis/myopathy, growth retardation in children

            Reproduction disorders: Hemorrhagic corpus luteum/hemorrhagic ovarian cyst

            Previous
            Next

            Warnings

            Contraindications

            Hypersensitivity to any component

            Cautions

            Hepatic impairment, elderly

            Avoid concomitant strong CYP3A4 inducers

            Inhibits CYP 2C9, 2D6, and 3A4

            Risk of severe CHF or left ventricular dysfunction, especially in patients with comorbidities

            In patients with hypereosinophilic syndrome with occult infiltration of HES cells within the myocardium, cases of cardiogenic shock/left ventricular dysfunction have been associated with HES cell degranulation upon initiation of imatinib therapy; reported to be reversible with the administration of systemic steroids, circulatory support measures, and temporarily withholding imatinib

            If anticoagulation required, use LMW or standard heparin instead of warfarin

            Associated with anemia, neutropenia, and thrombocytopenia; CBC counts should be performed weekly for the first month, biweekly for the second month, and periodically thereafter

            Hemorrhage may occur

            Sometimes associated with GI irritation; should be taken with food and a large glass of water to minimize this problem.; there have been rare reports, including fatalities, of gastrointestinal perforation

            Avoid pregnancy; risk of embryo-fetal toxicity

            Often associated with edema and occasionally serious fluid retention; probability increases with dose and age >65 yr; investigate unexpected raid weight gain and provide appropriate treatment

            Growth retardation may occur in children and adolescents

            Bullous dermatologic reactions reported and include erythema multiforme and Stevens-Johnson syndrome

            Cases of tumor lysis syndrome reported, including fatal cases

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy Category: D; postmarket reports of spontaneous abortions and infant congenital anomalies Teratogenic in rats at doses approximating human dose of 800 mg/day that includes exencephaly or encephalocele; absent/reduced frontal and absent parietal bones

            Lactation: enters breast milk; not recommended

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Protein-tyrosine kinase inhibitor, specific for abnormal BCR-ABL tyrosine kinase produced by Philadelphia chromosome in CML/ALL

            Absorption

            Bioavailability: 98%

            Peak Plasma Time: 2-4 hr

            Distribution

            Protein Bound: 95%

            Metabolism

            Metabolized mostly by CYP3A4

            Enzymes inhibited: CYP2D6, CYP3A4

            Elimination

            Half-Life: 18 hr (parent drug); 40 hr (metabolite)

            Clearance: 8-14 L/hr

            Excretion: Feces (68%)

            Dialyzable: no

            Pharmacogenomics

            Tyrosine kinase inhibitors (TKIs) inhibit activity of BCR-ABL fusion protein, resulting in both hematologic response (ie, normal cell counts in the peripheral blood and normal bone marrow morphology), as well as cytogenetic response (ie, disappearance or reduction of the Philadelphia [Ph] chromosome)

            NCCN clinical practice guidelines recommends TKIs in CML with confirmed BCR-ABL transcripts in bone marrow or evidence of translocation on cytogenetics

            Genetic testing laboratories

            • The following companies currently offer FISH and/or transcript quantification testing for BCR-ABL
            • Asuragen (http://www.asuragen.com/)
            • Dako (http://www.dakousa.com/)
            • Invitrogen (http://www.invitrogen.com/)
            • Ipsogen (http://www.ipsogen.com)
            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.